BBRI Scientist Gets Grant to Study Breast Cancer Therapy
A scientist at Watertown’s Boston Biomedical Research Institute thinks he has a way to block breast cancer tumors before they start.
Dr. Ruben Gonzalez was recently awarded a grant to continue his work researching leptin, a protein found in greater amounts in obese or menopausal women who have a higher rate of breast cancer. Cancer cells use leptin to grow and develop blood vessels for tumors, but blocking leptin signaling stops their growth, Gonzalez found.
Innovative Breast Cancer Study at Boston Biomedical Research Institute Receives Highly Competitive Cancer Research and Prevention Foundation Award
WATERTOWN, Mass. – June 29, 2005 – An innovative research study at Boston Biomedical Research Institute targeting a key protein in the uncontrolled production of breast cancer cells has received the highly prestigious Cancer Research and Prevention Foundation award. This novel approach by Boston Biomedical’s Dr. Ruben Rene Gonzalez focuses on leptin, a protein primarily known for its relation to obesity and reproduction. The increased leptin levels which accompany obesity and menopause have been shown to increase the risk for development of breast cancer.
Groundbreaking Breast Cancer Study at Boston Biomedical Research Institute Receives Prestigious Susan G. Komen Foundation Grant Award
WATERTOWN, Mass. – May 26, 2005 – An innovative research study at Boston Biomedical Research Institute targeting a key protein in the uncontrolled production of breast cancer cells has received the highly prestigious Susan G. Komen Breast Cancer Foundation award. This novel approach by Boston Biomedical’s Dr. Ruben Rene Gonzalez focuses on leptin, a protein which has been shown to promote both the proliferation of cancer cells and the formation of new blood vessels necessary for cancer growth, a process known as angiogenesis.
Judah Folkman, BBRI Trustee, Shares New Directions in Cancer Research at the Spring 2005 Exploring Science Lecture
WATERTOWN, Mass. – May 27, 2005 – Dr. Judah Folkman, a world renowned pioneer in cancer research and member of Boston Biomedical Research Institute’s Board of Trustees, was the featured speaker at the Spring 2005 Exploring Science Lecture on May 12. Dr. Folkman’s talk, entitled “Can Human Cancer be Treated Before it is Symptomatic or Anatomically Located?” described his most recent research to detect the earliest signs of cancer in the human body, and his theory that some cancers may be able to be treated before becoming established as tumors. His work focuses on finding biomarkers, which are molecules in the urine, saliva or blood that signal the presence of disease. Dr. Folkman’s search for cancer biomarkers is the latest front in the battle for early detection and treatment. He shared several success stories in patients who have received this novel treatment, and he predicts this approach will be the beginning of a revolution in cancer therapy.
Thomas E. Leggat Elected Trustee of Boston Biomedical Research Institute
Watertown, Mass., – February 2, 2005 – Lincoln resident Thomas E. Leggat was recently elected Trustee of Watertown-based Boston Biomedical Research Institute. Mr. Leggat had been a Corporator at BBRI since 2001. He is a founder of Leggat, McCall and Werner, and Founder of The Leggat Company, Inc. Mr. Leggat is a longtime board member of the Boys & Girls Club, and was on the Board of the Unitarian Universalist Urban Ministry and is a longtime member of the Board of the Adolescent Consultation Services, Inc.
Terence McGowan to Lead Development Effort at Boston Biomedical Research Institute
Watertown, Mass., Jan. 5 /PRNewswire/ — Watertown based Boston Biomedical Research Institute has recently recruited Terence F. McGowan as Director of Institutional Advancement. Mr. McGowan will lead the fundraising and public relations efforts for BBRI, an independent, nonprofit biomedical research institute of 26 scientists doing discovery research in biochemistry, cell biology and molecular biology to uncover the causes of human disease. Mr. McGowan comes to BBRI from Dana-Farber Cancer Institute in Boston, where he was Associate Director of Corporate and Foundation Relations.